Dr. Reddy's Laboratories/RDY

$71.12

-0.42%
-
1D1W1MYTD1YMAX

About Dr. Reddy's Laboratories

Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company. The Company offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC). Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The Company’s segments include Pharmaceutical Services and Active Ingredients, Global Generics, and Others. The Pharmaceutical Services and Active Ingredients segment primarily consists of the Company’s business of manufacturing and marketing APIs and intermediates. The Global Generics segment consists of the Company’s business of manufacturing and marketing prescription and OTC finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

Ticker

RDY

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Gunupati Prasad

Employees

25,863

Headquarters

Hyderabad, India

RDY Metrics

BasicAdvanced
$12.16B
Market cap
19.04
P/E ratio
$3.75
EPS
0.58
Beta
$0.48
Dividend rate
0.68%
Dividend yield
$12.16B
0.58211
$77.72
$53.12
190.5K
$0.48
2.548
1.871
2.297
7.411
12.81%
18.249
15.31%
21.39%
20.71%
19.044
3.744
3.709
4.481
25.488
0.64%
0.67%
0.68%
14.34%
43.39%
12.09%
32.14%
13.51%

What the Analysts think about RDY

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 3 analysts.
9.88% upside
High $79.85
Low $75.73
$71.12
Current price
$78.15
Average price target

RDY Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
19.11% profit margin
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
₹72.15B
4.86%
Net income
₹13.79B
-6.83%
Profit margin
19.11%
-11.16%

RDY Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 17.58%
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
₹57.62
₹84.36
₹88.91
₹82.81
-
Expected
₹52.50
₹57.03
₹69.65
₹70.43
₹67.78
Surprise
9.74%
47.93%
27.65%
17.58%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for Dr. Reddy's Laboratories stock?

Dr. Reddy's Laboratories (RDY) has a market cap of $12.16B as of April 16, 2024.

What is the P/E ratio for Dr. Reddy's Laboratories stock?

The price to earnings (P/E) ratio for Dr. Reddy's Laboratories (RDY) stock is 19.04 as of April 16, 2024.

Does Dr. Reddy's Laboratories stock pay dividends?

Yes, the Dr. Reddy's Laboratories (RDY) stock pays dividends to shareholders. As of April 16, 2024, the dividend rate is $0.48059 and the yield is 0.68%. Dr. Reddy's Laboratories has a payout ratio of 12.81% on a trailing twelve-month basis.

When is the next Dr. Reddy's Laboratories dividend payment date?

The next Dr. Reddy's Laboratories (RDY) dividend payment date is unconfirmed.

What is the beta indicator for Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (RDY) has a beta rating of 0.58. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Dr. Reddy's Laboratories stock price target?

The target price for Dr. Reddy's Laboratories (RDY) stock is $78.15, which is 9.88% above the current price of $71.12. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Dr. Reddy's Laboratories stock

Buy or sell Dr. Reddy's Laboratories stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing